May 15, 2026 — The U.S. Food and Drug Administration (FDA) has approved IMMGOLIS (golimumab-sldi) and IMMGOLIS INTRI (golimumab-sldi), the first biosimilar versions of Johnson & Johnson's Simponi (golimumab) and Simponi Aria (golimumab). The approval marks a significant milestone: these are the first golimumab biosimilars to receive both biosimilarity and interchangeability designations, enabling pharmacy-level substitution without physician intervention in states that permit it.
The products are developed by Bio-therapeutics and will be commercialized in the United States by Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals. IMMGOLIS is administered as a subcutaneous injection via a single-dose prefilled syringe, while IMMGOLIS INTRI is delivered as an intravenous infusion from a single-dose vial.
Golimumab is a fully human monoclonal antibody (IgG1κ) that targets tumor necrosis factor alpha (TNF-α), a pro-inflammatory cytokine central to the pathogenesis of multiple autoimmune conditions. Simponi and Simponi Aria collectively generated approximately $2 billion in U.S. sales during 2025, making golimumab one of the largest biosimilar opportunities in the TNF inhibitor class.
The approval addresses two critical therapeutic areas:
Rheumatoid arthritis (RA): IMMGOLIS is approved for use in combination with methotrexate for adult patients with moderately to severely active RA
Ulcerative colitis (UC): IMMGOLIS is approved for treating adult patients with moderately to severely active UC, expanding biosimilar access beyond injectable-only formulations
The interchangeability designation is a critical differentiator in the biosimilar market. While standard biosimilars require physician authorization for substitution, interchangeable biosimilars can be dispensed at the pharmacy level — subject to state pharmacy laws — without requiring a new prescription or prescriber consultation.
This designation provides several commercial advantages:
Automatic substitution: Pharmacists can dispense IMMGOLIS in place of Simponi or Simponi Aria without prescriber involvement
Preferred formulary placement: Payers and pharmacy benefit managers increasingly favor interchangeable biosimilars for formulary positioning
Patient access expansion: Reduced administrative barriers facilitate broader adoption among healthcare providers and patients
Cost reduction: Interchangeable biosimilars typically offer 20-35% cost reductions compared to reference products
Golimumab presents complex manufacturing challenges that create opportunities for specialized suppliers. As a fully human monoclonal antibody, its production requires sophisticated bioprocessing capabilities:
Cell line development: CHO (Chinese Hamster Ovary) cell engineering for high-titer antibody expression
Upstream processing: Fed-batch or perfusion bioreactor operations with serum-free, animal-component-free media
Downstream purification: Protein A capture chromatography followed by ion exchange and viral filtration steps
Formulation science: High-concentration liquid formulations (100 mg/mL for SC injection) require careful protein engineering to maintain stability and syringeability
Fill-finish: Dual presentation formats — prefilled syringes for SC administration and vials for IV infusion — demand flexible manufacturing lines
The dual SC/IV approval of IMMGOLIS and IMMGOLIS INTRI is particularly noteworthy from a manufacturing perspective. Prefilled syringe assembly requires specialized equipment for glass barrel processing, elastomeric plunger insertion, and tungsten-free needle attachment, while IV vial fill-finish involves aseptic processing with different component specifications.
The golimumab approval accelerates the broader TNF inhibitor biosimilar market, which now includes interchangeable options across multiple reference products:
Adalimumab (Humira): Multiple interchangeable biosimilars now available
Infliximab (Remicade): Established biosimilar competition
Etanercept (Enbrel): Biosimilar options available with varying interchangeability status
Golimumab (Simponi): Now with first interchangeable biosimilar pair
Market analysts expect competitive intensity to drive golimumab prices down by 30-50% within the first two years of IMMGOLIS availability, significantly improving patient access to this important TNF inhibitor therapy.
The expanding TNF inhibitor biosimilar market presents multiple strategic opportunities across the biopharmaceutical supply chain:
Custom antibody manufacturing: Recombinant protein production partnerships with biosimilar developers scaling up commercial supply
Raw material supply: Culture media components, chromatography resins, and filtration membranes for high-volume biologics manufacturing
Prefilled syringe components: Glass barrels, tungsten-free needles, and elastomeric plungers for IMMGOLIS SC presentation
Analytical services: Comparability studies, biosimilarity characterization, and release testing for regulatory submissions
Regulatory support: DMF filings and global regulatory dossier preparation for multiple markets
The FDA's approval of interchangeable golimumab biosimilars represents the continued maturation of the U.S. biosimilar market. For pharmaceutical suppliers and contract manufacturers, the key strategic imperative is early engagement with biosimilar developers during clinical development and process validation phases. Companies that establish supply relationships during these critical stages are best positioned to capture long-term commercial volume as IMMGOLIS scales to significant market share in the TNF inhibitor class.
